Medical University Of Gdansk — Sponsor Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

9 Recruiting

6 Completed trials

3 Countries active

33 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 10 Phase II: 3 Phase I/II: 1 Phase IV: 1

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Shprintzen-Goldberg syndrome 1 Acute coronary syndrome 1 Duchenne muscular dystrophy 1 Ischaemic stroke 1 Nephrotic syndrome 1 Colitis ulcerative 1 Interstitial lung disease 1 Arterial tortuosity syndrome 1 Heart failure with preserved ejection fraction 1 Marfan's syndrome 1 Systemic mastocytosis 1 Anxiety 1

Top IMPs

ALLOGENEIC WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELLS 1 ALTEPLASE 1 ANDEXANET ALFA 1 DUPILUMAB 1 FEXOFENADINE HYDROCHLORIDE 1 GLUCOSE MONOHYDRATE 1 INFLIXIMAB 1 LEVOSIMENDAN 1 METOPROLOL TARTRATE 1 NINTEDANIB 1 OXYGEN 1 PIRFENIDONE 1

All trials

15 total

The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement Recruiting

2023-509111-89-00 Phase III 1 country DUPILUMAB; FEXOFENADINE HYDROCHLORIDE; SODIUM CHLORIDE
A clinical trial in children and adolescents with primary malignant liver cancer - Hepatoblastoma and Hepatocarcinoma Recruiting

2024-514635-26-00 Phase III 1 country SODIUM THIOSULFATE
Treatment of acute ischemic stroke due to occlusion of a large vessel by mechanical thrombectomy in patients with unknown onset or not meeti… Recruiting

2024-515062-13-00 Phase III 1 country
Evaluation of the Efficacy of Valsartan in Slowing Down Aortic Root Dilatation in Children and Young Adults with Marfan Recruiting

2024-515059-39-00 Phase III 1 country VALSARTAN
Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseas… Recruiting

2024-514433-38-00 Phase I/II 1 country ALLOGENEIC WHARTON'S JELLY-DERIVED MESENCHYMAL STEM CELLS; NINTEDANIB; PIRFENIDO…
Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation… Recruiting

2024-515064-31-00 Phase II 1 country
A multicentre study evaluating the safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtP… Recruiting

2024-518509-17-00 Phase II 1 country ALTEPLASE; ANDEXANET ALFA
Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrom… Recruiting

2024-515058-26-00 Phase III 1 country RITUXIMAB
Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ… Recruiting

2024-515063-66-00 Phase II 3 countries
Impact of trimetazidine on endothelial function and biomarkers correlating with the prognosis of heart failure with preserved ejection fract… Ended

2023-506138-65-00 Phase IV 1 country TRIMETAZIDINE DIHYDROCHLORIDE
Study of Levosimendan Therapy in low ejection fraction Takotsubo Syndrome Ended

2024-515060-32-00 Phase III 1 country GLUCOSE MONOHYDRATE; LEVOSIMENDAN
The effect of sertraline on anxiety-depressive symptoms, endothelial dysfunction and biomarkers in heart failure patients with preserved eje… Ended

2024-515061-33-00 Phase III 1 country SERTRALINE
Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Und… Ended

2024-515056-20-00 Phase III 1 country TICAGRELOR
Metoprolol Safety and Efficacy in the Prevention of Cardiomyopathy in Patients with Duchenne Muscular Dystrophy (DMD) Ended

2024-515057-19-00 Phase III 1 country METOPROLOL TARTRATE
Evaluating the efficacy and safety of hyperbaric oxygen therapy as an adjuvant treatment compared to biologic therapy alone in moderate to s… Ended

2023-507450-32-00 Phase III 1 country INFLIXIMAB; OXYGEN; USTEKINUMAB; VEDOLIZUMAB

Showing 1–15 of 15 trials

← All sponsors A–Z